Prophase Labs

Prophase Labs Net Debt per Share

The Net Debt per Share of Prophase Labs (PRPH) as of Oct 22, 2026 is 4.17 USD. In the previous year, Net Debt per Share was 11.68 USD — a change of -64.31% (lower).

Net Debt per Share

4.17USD

YoY

-64.31%

Last updated:

Net Debt per Share of Prophase Labs is 2025 4.17 USD. Net Debt per Share of Prophase Labs was 2024 11.68 USD. It decreases by -64.31% lower compared to the previous year.

The Prophase Labs Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-2.27 USD
Jan 1, 2019
-0.21 USD
Jan 1, 2020
3.06 USD
Jan 1, 2021
-1.28 USD
Jan 1, 2022
-5.12 USD
Jan 1, 2023
6.70 USD
Jan 1, 2024
11.68 USD
Jan 1, 2025
4.17 USD
The Prophase Labs Net Debt per Share history
YEARNet Debt per ShareYoY
4.17USD-64.31%
11.68USD+74.16%
6.70USD-230.95%
-5.12USD+301.11%
-1.28USD-141.68%
3.06USD-1,544.01%
-0.21USD-90.67%
-2.27USD-78.80%
-10.72USD-2,191.33%
0.51USD-629.80%
-0.10USD-92.99%
-1.38USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prophase Labs Stock analysis

What does Prophase Labs do? ProPhase Labs, Inc. generates revenue through the sale of over-the-counter consumer healthcare products and dietary supplements. The company develops and markets TK Supplements, featuring LEGENDZ XL for male sexual enhancement, TRIPLE EDGE XL for daily energy and stamina, and SUPER PROSTAFLOW plus for prostate and urinary health. ORXx Complete, a dietary supplement, and ORXx cough/cold drops are also sold to national wholesalers, distributors, and retail chains including pharmacies and mass merchandise stores. The firm targets health-conscious consumers seeking natural solutions through its OTC drug and supplement lines. Its products are distributed via national wholesalers and retailers such as independent and chain drugstores, food stores, and mass merchandise outlets. ProPhase Labs focuses on direct sales to these established retail segments without third-party branding or partnerships. Revenue streams are derived from the consistent demand for male enhancement, energy, and health supplements within the OTC market. The company's product portfolio caters specifically to customers interested in natural health products, with no additional services or digital platforms beyond physical product sales. Prophase Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prophase Labs stock

Net Debt per Share of Prophase Labs is 4.17 USD in 2025.

Net Debt per Share of Prophase Labs changed from 11.68 USD to 4.17 USD, representing a -64.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Prophase Labs since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Prophase Labs

All Key Metrics — Prophase Labs